Apellis Pharmaceuticals, Inc.
APLS
Rankning i aktier
#3320
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Aktiekurs
$41.03
Senast synkroniserad: 2026-05-15
Marknadsvärde
$5.25B
Förändring (1 dag)
0.00%
Förändring (1 år)
67.33%
Land
US
Handel Apellis Pharmaceuticals, Inc. (APLS)
Kategori
Healthcare
Rörelsemarginal för Apellis Pharmaceuticals, Inc. (APLS)
Rörelsemarginal per October 2026 TTM: 14.95%
Enligt de senaste finansiella rapporterna och aktiekursen för Apellis Pharmaceuticals, Inc. är företagets nuvarande rörelsemarginal (TTM) 14.95%. Vid slutet av 2023 var rörelsemarginalen -130.39%.
Historik för rörelsemarginal för Apellis Pharmaceuticals, Inc. från 2013 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | 14.95% | -170.82% |
| 2024 | -21.11% | -83.81% |
| 2023 | -130.39% | -83.46% |
| 2022 | -788.38% | -2.15% |
| 2021 | -805.67% | 844.85% |
| 2020 | -85.27% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 38.59% | -97.42% |
US
|
|
| -149.01% | -109.97% |
US
|
|
| 25.57% | -98.29% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.07% |
NL
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.